RENX.L Stock - Renalytix Plc
Unlock GoAI Insights for RENX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.00M | $2.29M | $3.40M | $2.97M | $1.49M |
| Gross Profit | $1.20M | $156,000 | $701,000 | $918,000 | $687,000 |
| Gross Margin | 40.0% | 6.8% | 20.6% | 30.9% | 46.1% |
| Operating Income | $-17,200,000 | $-29,608,000 | $-42,355,000 | $-53,183,000 | $-31,916,000 |
| Net Income | $-20,400,000 | $-33,456,000 | $-45,607,000 | $-45,276,000 | $-34,725,000 |
| Net Margin | -680.0% | -1461.6% | -1340.2% | -1524.4% | -2329.0% |
| EPS | $-0.21 | $-0.31 | $-0.55 | $-0.62 | $-0.49 |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
RENX.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.01 | — | — | — |
Q1 2025 | Mar 18, 2025 | $-0.01 | — | — | — |
Q1 2025 | Feb 13, 2025 | — | $-0.03 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.04 | — | — |
Q3 2024 | Sep 30, 2024 | $-0.01 | $-0.04 | -149.9% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.04 | $-0.07 | -90.4% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.04 | $-0.08 | -113.7% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.04 | $-0.09 | -115.8% | ✗ MISS |
Q2 2023 | Jun 9, 2023 | $-0.05 | $-0.10 | -124.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.06 | $-0.12 | -120.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q4 2022 | Nov 30, 2022 | $-0.05 | $-0.14 | -164.7% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $-0.07 | $-0.06 | +9.4% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.06 | $-0.17 | -189.4% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.18 | — | — |
Q4 2021 | Oct 21, 2021 | — | $-0.12 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.12 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.10 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.11 | — | — |
Latest News
Frequently Asked Questions about RENX.L
What is RENX.L's current stock price?
What is the analyst price target for RENX.L?
What sector is Renalytix Plc in?
What is RENX.L's market cap?
Does RENX.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RENX.L for comparison